RE:RE:AstraZeneca's ADC disappoints - on severe adverse events March 01, 2024 - Pfizer is pivoting from Covid-19 to zoom in on cancer, with a laser focus on next-gen antibody-drug conjugates (ADCs), small molecules and bispecific antibodies.
Pfizer’s new emphasis is in four main types of cancer: breast cancer, including three main hormonal subtypes; genitourinary cancer, such as prostate and urothelial cancers; hematology-oncology, including multiple myeloma and lymphomas; and thoracic cancers, which includes lung and head and neck cancers. The pharma’s previous oncology focus areas were genitourinary, breast, hematology and precision medicine, a company spokesperson confirmed.
The Big Pharma is exploring the four core areas using three modalities: small molecules, ADCs and bispecific antibodies, including other immuno-oncology biologics. The company’s next-gen ADC platform combines Pfizer's protein engineering and antibody design capabilities with Seagen’s ADC tech to take aim at novel targets and improved, differentiated payloads, chief scientific officer for oncology R&D, Jeff Settleman, Ph.D., said during the event.
https://www.fiercebiotech.com/biotech/after-covid-decline-pfizer-builds-out-cancer-pipeline-and-leans-adcs